课题基金 / 基金详情

An Exploration of Neurocognitive Contributors to Functional Recovery Following Cognitive Behavioural Therapy and Intravenous Ketamine for Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial

An Exploration of Neurocognitive Contributors to Functional Recovery Following Cognitive Behavioural Therapy and Intravenous Ketamine for Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
认知行为疗法和静脉注射氯胺酮治疗难治性抑郁症后对功能恢复的神经认知因素的探索：一项随机、咪达唑仑对照临床试验
批准号：
475697
负责人：
Lipsitz Orly
金额：
$7.65万
依托单位：
University of Toronto Scarborough (ON)
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-11-01 至 2025-11-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=475697&lang=en
关键词：
Cognition Cognitive Behavioural Therapy Functional Recovery Ketamine Major Depressive Disorder Randomized Clinical Trial Treatment-Resistant Depression

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
重度抑郁症（MDD）是年轻人残疾的主要原因，也是安大略残疾索赔的最大增长原因。MDD中的功能障碍与大量的经济和医疗保健成本、创伤性休克的增加、
英文摘要
Major depressive disorder (MDD) is a leading cause of disability among young adults and is the largest growing cause of disability claims in Ontario. Functional impairment in MDD is associated with substantial economic and healthcare costs, increased vuln
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金